ＩＬ－１５異源二聚體蛋白及其用途

• 收藏
• 分享

专利权人:

SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.;JIANGSU HENGRUI MEDICINE CO., LTD.

发明人:

QU, XIANGDONG,屈向东,屈向東,YE, XIN,叶鑫,葉鑫,YUAN, JIJUN,袁纪军,袁紀軍,ZHANG, LEI,张蕾,張蕾,CHEN, KAN,陈侃,陳侃,ZHANG, LIANSHAN,张连山,張連山,CAO, GUOQING,曹国庆,曹國慶,XU, ZHIBIN,许志宾,許志賓,TAO, WEIKANG,陶维康,陶維康

申请号：

TW104100499

公开号：

TW201609807A

申请日:

2015.01.08

申请国别(地区):

TW

年份:

2016

代理人:

摘要：

The present invention relates to an IL-15 heterodimer protein and pharmaceutical uses thereof. Furthermore, the present invention relates to an IL-15/IL-15R α heterodimer protein. The IL-15 heterodimer protein comprises protein(I) and protein(II), wherein the said protein(I) was fused by IL-15 or variants thereof and the first Fc variant； wherein the said protein(II) is the second Fc variant or wasfused by IL-15 R α or variants thereof and the second Fc variant. The first Fc variant and the second Fc variant can be formed via “Knob-into-Hole” mode. The IL-15 heterodimer of the present invention has significant anti-tumor activity, and has a better biological activity and extended in vivo half-life compared to IL-15 molecule alone.本發明涉及一種IL-15異源二聚體蛋白及其用途，還涉及一種IL-15/IL-15R α異源二聚體蛋白。IL-15異源二聚體蛋白包含蛋白(I)和蛋白(II)，蛋白(I)由IL-15或其變體和第一Fc變體重組而成；蛋白(II)是第二Fc變體，或由IL-15 R α或其變體和第二Fc變體重組而成，第一Fc變體和第二Fc變體間以Knob-into-Hole形式連接。本發明的IL-15異源二聚體具有明顯的抑瘤活性，比IL-15單一分子具有更好的生物活性及延長的體內半衰期。

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/